# A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

> **NCT01594229** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 60 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** ABT-199
- **DRUG:** Rituximab
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT01594229
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-21
- **Primary completion:** 2020-07-14
- **Final completion:** 2020-07-14
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01594229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01594229, "A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01594229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*